aspirin and Anosmia
aspirin has been researched along with Anosmia in 2 studies
Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.
Anosmia: Complete or severe loss of the subjective sense of smell. Loss of smell may be caused by many factors such as a cold, allergy, OLFACTORY NERVE DISEASES, viral RESPIRATORY TRACT INFECTIONS (e.g., COVID-19), aging and various neurological disorders (e.g., ALZHEIMER DISEASE).
Research Excerpts
| Excerpt | Relevance | Reference |
|---|---|---|
| "Aspirin-exacerbated respiratory disease (AERD) is characterized by eosinophilic chronic rhinosinusitis with nasal polyps, asthma, and upper-/lower-respiratory tract reactions to nonsteroidal antiinflammatory drugs." | 5.05 | Nasal Polyposis and Aspirin-Exacerbated Respiratory Disease. ( Luskin, K; Thakrar, H; White, A, 2020) |
| "The impact of anosmia on quality-of-life (QoL) for patients with aspirin-exacerbated respiratory disease (AERD) is poorly understood." | 4.12 | Loss of smell in patients with aspirin-exacerbated respiratory disease impacts mental health and quality of life. ( Bensko, JC; Buchheit, KM; Gakpo, D; Laidlaw, TM; Lundberg, M; Maurer, R; Mullur, J; Tchekmedyian, R, 2022) |
Research
Studies (2)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Tchekmedyian, R | 1 |
| Lundberg, M | 1 |
| Buchheit, KM | 1 |
| Maurer, R | 1 |
| Gakpo, D | 1 |
| Mullur, J | 1 |
| Bensko, JC | 1 |
| Laidlaw, TM | 1 |
| Luskin, K | 1 |
| Thakrar, H | 1 |
| White, A | 1 |
Reviews
1 review available for aspirin and Anosmia
| Article | Year |
|---|---|
Nasal Polyposis and Aspirin-Exacerbated Respiratory Disease.
Topics: Adrenal Cortex Hormones; Anosmia; Aspirin; Asthma, Aspirin-Induced; Biological Products; Humans; Imm | 2020 |
Other Studies
1 other study available for aspirin and Anosmia
| Article | Year |
|---|---|
Loss of smell in patients with aspirin-exacerbated respiratory disease impacts mental health and quality of life.
Topics: Anosmia; Aspirin; Asthma, Aspirin-Induced; Female; Humans; Mental Health; Quality of Life; Sinusitis | 2022 |